ATX101-03

Phase 1b/2a study investigating ATX-101 in combination with platinum-based chemotherapy in platinum-sensitive, recurrent ovarian, fallopian tube and primary peritoneal cancer

Study Link: https://clinicaltrials.gov/ct2/show/NCT04814875

Regeneron R1979-ONC-1625

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Study Link: https://clinicaltrials.gov/ct2/show/NCT03888105

APG-2575CU101 (CLL,SLL)

A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED)

Study Link: https://clinicaltrials.gov/ct2/show/NCT04215809

AND

https://clinicaltrials.gov/ct2/show/NCT04494503

SSG XXII GIST Study

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients with Operable GIST with a High Risk for Recurrence: A randomised phase III multicenter study

Study Link: https://clinicaltrials.gov/ct2/show/NCT02413736

IPSEN-D-FR-60010-015 SIRACUSA

A Phase I, Randomised, Open-Label, Single Dose, Two-Treatment, Two-Way Crossover, Two Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination with Anti Cancer Agents in Adult Participants with Metastatic Pancreatic Adenocarcinoma

Study Link: https://clinicaltrials.gov/ct2/show/NCT05383352

Seattle Genetics - SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT04032704

Abbisko ABSK043-101

A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor

Study Link: https://clinicaltrials.gov/ct2/show/NCT04964375

Atridia SHR-A1904-I-104

An Open-label, Single-arm, Multi-center Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHRA1904 in Subjects with Advanced Solid Tumours Expressing Claudin 18.2

Study Link: https://clinicaltrials.gov/ct2/show/NCT05277168

Hanmi HM-EZHI-101

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients with Advanced or Metastatic Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT05598151

NAV-1003

A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

Study Link: https://clinicaltrials.gov/ct2/show/NCT05480865

ATG-037-001

A Phase I/Ib, Multi-centre, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumours

Study Link: https://clinicaltrials.gov/ct2/show/NCT05205109

Revolution RMC-6291-001

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT05462717

LM302-01-201

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT05188664

LOXO-RAS-200001

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT04956640

TCTLR-101

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Study Link: https://clinicaltrials.gov/ct2/show/NCT04799054

ICP-CL-00303

A multi-center open-label, phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-192 in patients with advanced solid tumors and FGF/FGFR gene alterations

Study Link: https://clinicaltrials.gov/ct2/show/NCT04565275

DS1062-A-U303

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

Study Link: https://clinicaltrials.gov/ct2/show/NCT05555732

DREAM3R Mesothelioma Trial

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Study Link: https://clinicaltrials.gov/ct2/show/NCT04334759

Apollomics APL-101-01 SPARTA

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT03175224

WO41554 GDC-0077 Breast Study

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Study Link: https://clinicaltrials.gov/ct2/show/NCT04191499

CELC-G-301 (VIKTORIA-1)

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)

Study Link: https://clinicaltrials.gov/ct2/show/NCT05501886

OP-1250-002

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

Study Link: https://clinicaltrials.gov/ct2/show/NCT05266105

SGNTUC-028 (HER2CLIMB-05)

A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer

Study Link: https://clinicaltrials.gov/ct2/show/NCT05132582

Seagen RC48-G001

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma

Study Link: https://clinicaltrials.gov/ct2/show/NCT04879329